NMDA or AMPA/kainate receptor blockade prevents acquisition of conditioned place preference induced by D(2/3) dopamine receptor stimulation in rats.
BACKGROUND
Recent experiments from this laboratory demonstrated synergistic effects of AMPA/kainate receptor blockade and D(2/3) dopamine (DA) receptor stimulation on brain stimulation reward and locomotor activity.


OBJECTIVE
Using place conditioning, this study explored further the interaction between DA and glutamate (Glu) using the N-methyl-D-aspartate (NMDA) receptor antagonist MK-801, the AMPA/kainate receptor antagonist NBQX, and the D(2/3) DA receptor agonist 7-OH-DPAT.


METHODS
Effects of these compounds, alone and combined, were measured in male Sprague--Dawley rats using an unbiased two-compartment place conditioning procedure.


RESULTS
7-OH-DPAT (0.03--5.0 mg kg(-1), s.c.) administered immediately prior to conditioning was ineffective; when administered 15 min prior to conditioning, only the highest dose (5.0 mg kg(-1), s.c.) induced conditioned place preference (CPP). Acquisition of 7-OH-DPAT-induced CPP was blocked by MK-801 (0.06 or 0.13 mg kg(-1), i.p.) or NBQX (0.5 microg) microinjected into the nucleus accumbens (NAS) shell subregion. Intra-NAS shell administration of 7-OH-DPAT (5.0 microg) or NBQX (0.5 microg), alone or combined, failed to induce place conditioning, and this lack of effect was not due to state dependency. Administration of MK-801 or 7-OH-DPAT (5.0 mg kg(-1)) during the conditioning phase acutely increased horizontal activity, but neither compound, alone or combined, induced conditioned locomotor effects.


CONCLUSIONS
Acquisition of place conditioning induced by systemic administration of 7-OH-DPAT is blocked by systemic NMDA receptor antagonism by MK-801 or by the AMPA/kainate receptor antagonist NBQX microinjected into the NAS shell subregion.
Biondo
Anna-Maria
AM
Department of Sociology, University of Alberta, Edmonton, Alberta, Canada.
Clements
Robert L H
RL
Hayes
David J
DJ
Eshpeter
Brendan
B
Greenshaw
Andrew J
AJ
D000818:Animals; D002755:Choice Behavior; D003213:Conditioning, Psychological / Q000187:drug effects*; D016291:Dizocilpine Maleate / Q000494:pharmacology; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology*; D008297:Male; D009714:Nucleus Accumbens / Q000187:drug effects / Q000502:physiology; D011810:Quinoxalines / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D018091:Receptors, AMPA / Q000037:antagonists & inhibitors*; D017448:Receptors, Dopamine D2 / Q000502:physiology*; D050637:Receptors, Dopamine D3; D018092:Kainic Acid Receptors / Q000037:antagonists & inhibitors*; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors*; D013764:Tetrahydronaphthalenes / Q000494:pharmacology
D016291:Dizocilpine Maleate; D018691:Excitatory Amino Acid Antagonists; D011810:Quinoxalines; D018091:Receptors, AMPA; D017448:Receptors, Dopamine D2; D050637:Receptors, Dopamine D3; D018092:Kainic Acid Receptors; D016194:Receptors, N-Methyl-D-Aspartate; D013764:Tetrahydronaphthalenes; C493595:Drd3 protein, rat; C062865:2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline; C031349:7-hydroxy-2-N,N-dipropylaminotetralin
J Neural Transm Gen Sect. 1994;95(1):71-4
7857588
Prog Neuropsychopharmacol Biol Psychiatry. 1988;12(2-3):315-22
2968613
Brain Res. 1995 Oct 30;697 (1-2):76-82
8593597
Behav Pharmacol. 1998 Sep;9(5-6):457-67
9832931
J Pharmacol Exp Ther. 1992 Feb;260(2):742-7
1371159
Psychopharmacology (Berl). 1996 Dec;128(4):413-20
8986012
Pharmacol Biochem Behav. 1996 Oct;55(2):209-14
8951956
Eur J Pharmacol. 1995 Feb 14;274(1-3):47-55
7768280
J Neural Transm Gen Sect. 1995;101(1-3):27-39
8695055
Brain Res. 1993 Aug 27;620(2):339-42
8369967
J Neurosurg. 1950 May;7(3):256-60
15415783
Pharmacol Biochem Behav. 2000 Nov;67(3):637-45
11164096
Behav Brain Res. 1989 Sep 1;34(3):239-46
2551338
Psychopharmacology (Berl). 1992;107(4):591-4
1534911
Eur J Pharmacol. 1996 Dec 30;318(2-3):251-6
9016912
Eur J Pharmacol. 1998 Dec 4;362(2-3):103-10
9874159
Psychopharmacology (Berl). 1997 Dec;134(3):266-76
9438676
Brain Res Bull. 1997;44(3):221-7
9323434
J Pharmacol Exp Ther. 1995 Dec;275(3):1355-66
8531103
Eur J Pharmacol. 1993 Nov 16;249(3):R9-10
8287911
Prog Neuropsychopharmacol Biol Psychiatry. 1997 Jul;21(5):839-52
9278955
Neurosci Res. 1995 Jul;22(4):427-30
7478308
Neurosci Lett. 1995 Jun 23;193(1):37-40
7566661
Neuroreport. 2003 Jan 20;14 (1):93-8
12544838
J Neurosci Methods. 1997 Dec 30;78(1-2):169-72
9497013
Psychopharmacology (Berl). 2000 May;150(1):102-11
10867982
J Neural Transm Gen Sect. 1995;101(1-3):115-26
8695042
Behav Brain Res. 2005 Mar 7;158(1):79-88
15680196
Pol J Pharmacol. 1994 Jan-Apr;46(1-2):79-81
7981776
J Pharmacol Exp Ther. 2003 Sep;306(3):1068-76
12805481
Pharmacol Biochem Behav. 1999 Aug;63(4):569-80
10462185
J Neurosci. 1998 Sep 15;18(18):7502-10
9736668
Pain. 1994 Sep;58(3):355-66
7838585
Behav Brain Res. 1997 Mar;84(1-2):99-107
9079776
Alcohol Alcohol. 1999 Mar-Apr;34(2):175-82
10344778
Behav Pharmacol. 1992 Aug;3(4):415-421
11224144
Psychopharmacology (Berl). 1999 Mar;143(1):39-46
10227078
Nature. 1990 Sep 13;347(6289):146-51
1975644
Brain Res. 1995 Mar 6;673(2):242-50
7606438
Psychopharmacology (Berl). 1989;99(1):87-90
2550989
Pol J Pharmacol. 1996 Jul-Aug;48(4):425-30
9112683
Eur J Pharmacol. 1994 Aug 22;261(3):R5-6
7813542
Neuropharmacology. 1993 May;32(5):509-10
8321432
Behav Pharmacol. 1996 Aug;7(4):303-314
11224423
Neurosci Lett. 1998 Feb 13;242(2):114-6
9533407
Proc Natl Acad Sci U S A. 1986 Sep;83(18):7104-8
3529096
Eur J Neurosci. 1999 Nov;11(11):4089-98
10583497
Psychopharmacology (Berl). 1985;87(2):225-32
3931151
Life Sci. 2002 Apr 26;70(23):2799-810
12269384
Science. 1983 Jun 17;220(4603):1304-6
6857251
Behav Pharmacol. 1996 Jan;7(1):105-109
11224401
Pharmacol Biochem Behav. 1994 May;48(1):111-8
8029281
Physiol Behav. 1989 Oct;46(4):755-8
2557649
Brain Res. 1993 Jul 23;617(2):267-73
8402155
J Pharmacol Exp Ther. 1997 May;281(2):928-40
9152403
Behav Pharmacol. 1993;4(4):429-442
11224212
Brain Res. 1982 Dec 16;253(1-2):185-93
6817850
Behav Neural Biol. 1994 Jul;62(1):50-9
7945145
Life Sci. 1981 Nov 2;29(18):1881-6
7311722
Eur J Pharmacol. 1996 Dec 19;317(2-3):191-6
8997600
Neuropharmacology. 1997 Jul;36(7):961-71
9257940
Brain Res Bull. 1996;40(3):201-7
8736582
Pol J Pharmacol. 2000 May-Jun;52(3):179-85
11055574
Eur J Pharmacol. 1996 Jun 13;306(1-3):23-32
8813611
J Pharmacol Exp Ther. 1999 Jul;290(1):9-15
10381753
Pharmacol Biochem Behav. 1999 Nov;64(3):591-5
10548276
Brain Res. 1991 Oct 18;562(1):164-8
1839240
Psychopharmacology (Berl). 1995 Dec;122(4):351-7
8657832
Pharmacol Biochem Behav. 1993 Jan;44(1):245-7
8430127
Pharmacol Biochem Behav. 1994 Apr;47(4):907-12
8029261
Proc Natl Acad Sci U S A. 1992 Sep 1;89(17 ):8155-9
1518841
Pharmacol Biochem Behav. 1999 Jan;62(1):159-64
9972859
Eur J Pharmacol. 1999 Dec 3;385(2-3):99-102
10607864
Eur J Pharmacol. 2001 Oct 5;428(2):203-14
11675037
J Comp Neurol. 1992 Jun 8;320(2):145-60
1377716